Skip to content

Exercise in Obese Diabetic Patients With Chronic Kidney Disease

Structured Exercise in Obese Diabetic Patients With Chronic Kidney Disease

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01036490
Acronym
EX-ODCKD
Enrollment
36
Registered
2009-12-21
Start date
2010-07-01
Completion date
2017-06-30
Last updated
2018-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease

Brief summary

Patients with type 2 diabetes, obesity, and chronic kidney disease are generally physically inactive, have a high mortality rate, and may benefit from an exercise program. This study seeks to determine if a structured exercise program will benefit the heart (improved exercise tolerance, decreased blood pressure) and/or the kidney (decreased protein loss in urine and stabilization of kidney function) and lead to improvements in diabetes, body composition, and quality of life.

Detailed description

Patients with type 2 diabetes, obesity, and chronic kidney disease (CKD) are generally physically inactive, have a high mortality rate, and may benefit from an exercise program. However, there have been no randomized controlled trials to determine the benefits of exercise training in this population. This study seeks to substantiate the hypothesis that increasing energy expenditure by exercise training in the obese diabetic patient with CKD will result in the following benefits: 1. Renal benefits, including reduction in proteinuria and stabilization of glomerular filtration rate (GFR) 2. Cardiovascular benefits, including decreased blood pressure, decreased heart rate, and increased exercise tolerance. 3. Improved glucose control (lower glycated hemoglobin), lipid control (decreased cholesterol with improved atherogenic profile) 4. Improved body composition (weight loss, increased lean body mass and decreased fat mass). 5. Decreased inflammation (assessed by high-sensitivity C-reactive protein), endothelial dysfunction (assessed by flow-mediated dilatation), and oxidative stress (assessed by reduced glutathione). 6. Increased health-related quality of life. In preparation for this proposal, the investigators performed a 24-week randomized controlled feasibility study comparing aerobic exercise plus optimal medical management to medical management alone in patients with type 2 diabetes, obesity (BMI \> 30 kg/m2), and stage 2-4 CKD (eGFR 15-90 mL/min/1.73m2) with persistent proteinuria of \> 200 mg/g. Subjects randomized to exercise underwent thrice weekly aerobic training for 6 followed by 18 weeks of supervised home exercise. The primary outcome variable was change in proteinuria. Exercise training resulted in a significant improvement in exercise duration during stress testing which persisted until 24 weeks. This was accompanied by significant decreases in resting systolic blood pressure and 24-hour proteinuria at 24 weeks. No changes were seen in the control group. The investigators concluded that exercise training in obese diabetic patients with CKD is feasible and results in a demonstrable training effect (increased exercise duration and decreased resting blood pressure). Moreover, it may decrease proteinuria and thus have a renoprotective effect. The investigators now propose a larger-scale randomized controlled trial to determine the effects of exercise on renal functions, cardiovascular fitness, inflammation, and oxidative stress in diabetic patients with CKD. This will be a 52-week randomized study based on the investigators' pilot study design with some modifications. As opposed to the 6-week training period and 18-week home exercise period utilized in the pilot study, subjects randomized to exercise will undergo 12 weeks of intensive exercise training in the exercise laboratory followed by 40 weeks of supervised home exercise training (total duration of study 1 year). Moreover, due to recent recommendations that resistance training be incorporated into exercise training regimens in type 2 diabetic patients, the investigators will incorporate resistance (strength) training in this proposal. The primary outcome variable will be change in proteinuria at 12 and 52 weeks. Secondary outcome variables will be change in albuminuria and estimated glomerular filtration rate (eGFR) at 12 and 52 weeks. In addition, the investigators will measure blood pressure (BP), glycated hemoglobin, lipid profile, C-reactive protein (CRP) levels, body weight and composition, endothelial dysfunction (by flow-mediated dilatation), and Quality of Life (QoL) evaluations. The Index of Coexistent Diseases (ICED) to measure comorbidities to determine if comorbid conditions had any influence on the outcomes of the study. The Center for Epidemiologic Studies Depression Scale (CES-D) will also be used to determine the influence of depression (covariate) on study outcomes and adherence with the study objectives. This study will directly address the effects of a structured exercise program in a patient population at high risk for cardiovascular complications. The investigators will specifically address the novel idea that exercise will not only improve cardiovascular fitness but will also ameliorate the renal complications resulting from diabetes.

Interventions

OTHERExercise

Exercise training for 12 weeks followed by home exercise for 40 weeks

Sponsors

VA Office of Research and Development
Lead SponsorFED

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diabetes mellitus * CKD Stages 2-4 * BMI \> 30 * Persistent proteinuria (urine protein/creatinine \> 200 mg/g for \> 3 mo) * On treatment with ACE inhibitor or ARB * On treatment with aspirin * On treatment with statin (if LDL \> 100)

Exclusion criteria

* Symptomatic neuropathy/retinopathy * Positive stress test due to coronary arterial disease * Symptomatic cardiovascular disease * Congestive heart failure (New York Heart Association Class III or IV) * Chronic obstructive pulmonary disease (FEV1 \< 50% predicted and/or requires supplemental oxygen support during exercise) * Complaints of angina during the stress test * Cerebrovascular disease/cognitive impairment * Renal transplant * Inability to walk on the treadmill * Any unforeseen illness or disability that would preclude exercise testing or training * Participation in a formal exercise program within the previous 12 weeks

Design outcomes

Primary

MeasureTime frame
Change in Proteinuria12 weeks minus baseline

Secondary

MeasureTime frame
Change in Albuminuria12 weeks minus baseline
Change in Estimated Glomerular Filtration Rate (eGFR)12 weeks minus baseline

Countries

United States

Participant flow

Recruitment details

Subjects were recruited from the outpatient medical clinics of Hines VA Hospital over the three-year period between January 2011 and January 2014

Participants by arm

ArmCount
Exercise
12-week (3 days per week) program of aerobic and resistance training followed by 40 weeks of a home exercise program plus nutritional counseling
18
Control
Nutritional counseling alone
18
Total36

Baseline characteristics

CharacteristicExerciseControlTotal
Age, Continuous65 years
STANDARD_DEVIATION 8.7
67 years
STANDARD_DEVIATION 7.5
66 years
STANDARD_DEVIATION 8
Body mass index36.2 kg/m^2
STANDARD_DEVIATION 4.8
37.4 kg/m^2
STANDARD_DEVIATION 4.2
37 kg/m^2
STANDARD_DEVIATION 4.5
Sex: Female, Male
Female
0 Participants0 Participants0 Participants
Sex: Female, Male
Male
18 Participants18 Participants36 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 180 / 18
serious
Total, serious adverse events
0 / 180 / 18

Outcome results

Primary

Change in Proteinuria

Time frame: 12 weeks minus baseline

ArmMeasureValue (MEDIAN)
ExerciseChange in Proteinuria-34 mg/g creatinine
ControlChange in Proteinuria-133 mg/g creatinine
p-value: 0.04t-test, 2 sided
Primary

Change in Proteinuria

Time frame: 52 weeks minus baseline

ArmMeasureValue (MEDIAN)
ExerciseChange in Proteinuria15 mg/g creatinine
ControlChange in Proteinuria-66 mg/g creatinine
p-value: 0.39t-test, 2 sided
Secondary

Change in Albuminuria

Time frame: 12 weeks minus baseline

ArmMeasureValue (MEDIAN)
ExerciseChange in Albuminuria-11 mg/g creatinine
ControlChange in Albuminuria-87 mg/g creatinine
Secondary

Change in Albuminuria

Time frame: 52 weeks minus baseline

ArmMeasureValue (MEDIAN)
ExerciseChange in Albuminuria-13 mg/g creatinine
ControlChange in Albuminuria-31 mg/g creatinine
Secondary

Change in Estimated Glomerular Filtration Rate (eGFR)

Time frame: 12 weeks minus baseline

ArmMeasureValue (MEAN)Dispersion
ExerciseChange in Estimated Glomerular Filtration Rate (eGFR)0.2 mL/min/1.73m^2Standard Deviation 4.7
ControlChange in Estimated Glomerular Filtration Rate (eGFR)-3.4 mL/min/1.73m^2Standard Deviation 8.9
p-value: 0.15t-test, 2 sided
Secondary

Change in Estimated Glomerular Filtration Rate (eGFR)

Time frame: 52 weeks minus baseline

ArmMeasureValue (MEAN)Dispersion
ExerciseChange in Estimated Glomerular Filtration Rate (eGFR)-2.0 mL/min/1.73m^2Standard Deviation 5.8
ControlChange in Estimated Glomerular Filtration Rate (eGFR)-3.1 mL/min/1.73m^2Standard Deviation 6
p-value: 0.58t-test, 2 sided

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026